Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Open Label Trial of Nivolumab in Combination With Ipilimumab Versus Pemetrexed With Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma
Conditions
Interventions
Nivolumab
Ipilimumab
+3 more
Locations
109
United States
Ucsf
San Francisco, California, United States
Local Institution - 0014
New Haven, Connecticut, United States
H. Lee Moffitt Cancer Center & Research Inst, Inc
Tampa, Florida, United States
Local Institution - 0002
Chicago, Illinois, United States
Univ Of Maryland Greenbaum Cancer Center
Baltimore, Maryland, United States
Local Institution - 0013
Detroit, Michigan, United States
Start Date
November 29, 2016
Primary Completion Date
March 25, 2020
Completion Date
April 28, 2023
Last Updated
May 21, 2024
NCT06051695
NCT06885697
NCT04115254
NCT06503146
NCT04665206
NCT06790706
Lead Sponsor
Bristol-Myers Squibb
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions